Reference on EC 3.4.17.20 - Carboxypeptidase U
Please use the Reference Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
REF. 
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Bajazar, L.; Nesheim, M.; Morser, J.; Tracy, P.B.
Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor
J. Biol. Chem.
273
2792-2798
1998
Homo sapiens
Boffa, M.B.; Wang, W.; Bajzar, l.; Nesheim, M.E.
Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respsct to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties
J. Biol. Chem.
273
2127-2135
1998
Homo sapiens
Kokame, K.; Zheng, X.; Sadler, J.E.
Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C
J. Biol. Chem.
273
12135-12139
1998
Homo sapiens
Cote, H.; Bajzar, L.; Stevens, W.K.; Samis, J.A.; Morser, J.; MacGillivray, R.T.A.; Nesheim, M.E.
Functional characterization of recombinant human meizothrombin and meizothrombin (desF1)
J. Biol. Chem.
272
6194-6200
1997
Homo sapiens
Sakharov, D.V.; Plow, E.F.; Rijken, D.C.
On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B
J. Biol. Chem.
272
14477-14482
1997
Homo sapiens
Nesheim, M.; Wang, W.; Boffa, M.; Nagashima, M.; Morser, J.; Bajzar, L.
Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis
Thromb. Haemost.
78
386-391
1997
Homo sapiens
Von dem Borne, P.A.K.; Bajzar, L.; Meijers, J.C.M.; Nesheim, M.E.; Bouma, B.N.
Thrombin-mediated activation of factor XI results in a thrombin-activable fibrinolysis inhibitor-dependent inhibition of fibrinolysis
J. Clin. Invest.
99
2323-2327
1997
Homo sapiens
Broze, G.J.
Thrombin-dependent inhibition of fibrinolysis
Curr. Opin. Hematol.
3
390-394
1996
Homo sapiens
Bajzar, L.; Morser, J.; Nesheim, M.
TAFI, or plasma procarboxypeptidase B couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
J. Biol. Chem.
271
16603-16608
1996
Homo sapiens
Broze, G.J.; Higuchi, D.A.
Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hepatitis plasma
Blood
88
3815-3823
1996
Homo sapiens
Tan, A.K.; Eaton, D.L.
Activation and characterization of procarboxypeptidase B from human plasma
Biochemistry
34
5811-5816
1995
Homo sapiens
Bajzar, L.; Manuel, R.; Nesheim, M.E.
Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
J. Biol. Chem.
270
14477-14484
1995
Homo sapiens
Wang, W.; Hendricks, D.F.; Scharpe, S.S.
Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen
J. Biol. Chem.
269
15937-15944
1994
Homo sapiens
Eaton, D.L.; Malloy, B.E.; Tsai, S.P.; Henzel, W.; Drayna, D.
Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma
J. Biol. Chem.
266
21833-21838
1991
Homo sapiens
Kawamura, T.; Okada, N.; Okada, H.
Elastase from activated human neutrophils activates procarboxypeptidase R
Microbiol. Immunol.
46
225-230
2002
Homo sapiens
Mao, S.S.; Colussi, D.; Bailey, C.M.; Bosserman, M.; Burlein, C.; Gardell, S.J.; Carroll, S.S.
Electrochemiluminescence assay for basic carboxypeptidases: inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor
Anal. Biochem.
319
159-170
2003
Chlorocebus aethiops, Canis lupus familiaris, Homo sapiens, Macaca mulatta, Rattus norvegicus
Lazoura, E.; Campbell, W.; Yamaguchi, Y.; Kato, K.; Okada, N.; Okada, H.
Rational structure-based design of a novel carboxypeptidase R inhibitor
Chem. Biol.
9
1129-1139
2002
Homo sapiens
Marx, P.F.; Hackeng, T.M.; Dawson, P.E.; Griffin, J.H.; Meijers, J.C.; Bouma, B.N.
Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage
J. Biol. Chem.
275
12410-12415
2000
Homo sapiens
Schneider, M.; Nagashima, M.; Knappe, S.; Zhao, L.; Morser, J.; Nesheim, M.
Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation
J. Biol. Chem.
277
9944-9951
2002
Homo sapiens
Marx, P.F.; Havik, S.R.; Marquart, J.A.; Bouma, B.N.; Meijers, J.C.
Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor
J. Biol. Chem.
279
6620-6628
2004
Homo sapiens
Sato, T.; Miwa, T.; Akatsu, H.; Matsukawa, N.; Obata, K.; Okada, N.; Campbell, W.; Okada, H.
Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not
J. Immunol.
165
1053-1058
2000
Mus musculus (Q9JHH6), Mus musculus
Suzuki, K.; Muto, Y.; Fushihara, K.; Kanemoto, K.; Iida, H.; Sato, E.; Kikuchi, C.; Matsushima, T.; Kato, E.; Nomoto, M.; Yoshioka, S.; Ishii, H.
Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxypho sphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B
J. Pharmacol. Exp. Ther.
309
607-615
2004
Homo sapiens, Rattus norvegicus
Kato, T.; Akatsu, H.; Sato, T.; Matsuo, S.; Yamamoto, T.; Campbell, W.; Hotta, N.; Okada, N.; Okada, H.
Molecular cloning and partial characterization of rat procarboxypeptidase R and carboxypeptidase N
Microbiol. Immunol.
44
719-728
2000
Rattus norvegicus
Campbell, W.D.; Lazoura, E.; Okada, N.; Okada, H.
Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N
Microbiol. Immunol.
46
131-134
2002
Homo sapiens
Komura, H.; Shimomura, Y.; Yumoto, M.; Katsuya, H.; Okada, N.; Okada, H.
Heat stability of carboxypeptidase R of experimental animals
Microbiol. Immunol.
46
217-223
2002
Cavia porcellus, Oryctolagus cuniculus, Homo sapiens, Rattus norvegicus
Bouma, B.N.; Marx, P.F.; Mosnier, L.O.; Meijers, J.C.
Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)
Thromb. Res.
101
329-354
2001
Papio sp., Canis lupus familiaris, Cavia porcellus, Oryctolagus cuniculus, Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa
Valnickova, Z.; Christensen, T.; Skottrup, P.; Th?gersen, I.B.; H?jrup, P.; Enghild, J.J.
Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation
Biochemistry
45
1525-1535
2006
Homo sapiens (Q96IY4), Homo sapiens
Polla, M.O.; Tottie, L.; Norden, C.; Linschoten, M.; Muesil, D.; Trumpp-Kallmeyer, S.; Aukrust, I.R.; Ringom, R.; Holm, K.H.; Neset, S.M.; Sandberg, M.; Thurmond, J.; Yu, P.; Hategan, G.; Anderson, H.
Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)
Bioorg. Med. Chem.
12
1151-1175
2004
Homo sapiens
Willemse, J.L.; Hendriks, D.F.
Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge
Clin. Chem.
52
30-36
2006
Homo sapiens
Stroemqvist, M.; Hansson, L.; Andersson, J.O.; Johansson, T.; Edlund, M.; Enoksson, M.; Goossens, F.; Scharpe, S.; Hendriks, D.
Properties of recombinant human plasma procarboxypeptidase U produced in mammalian and insect cells
Clin. Chim. Acta
347
49-59
2004
Homo sapiens (Q96IY4), Homo sapiens
Marx, P.F.
Thrombin-activatable fibrinolysis inhibitor
Curr. Med. Chem.
11
2335-2348
2004
Homo sapiens, Mus musculus
Ceresa, E.; Van de Borne, K.; Peeters, M.; Lijnen, H.R.; Declerck, P.J.; Gils, A.
Generation of a stable activated thrombin activable fibrinolysis inhibitor variant
J. Biol. Chem.
281
15878-15883
2006
Homo sapiens
Marx P. , M.P.; Meijers J. C. , M.J.
Mechanism of action of carboxypeptidase U: staying above the threshold
J. Thromb. Haemost.
2
414-415
2004
Homo sapiens
Guimaraes, A.H.; Bertina, R.M.; Rijken, D.C.
A new functional assay of thrombin activatable fibrinolysis inhibitor
J. Thromb. Haemost.
3
1284-1292
2005
Homo sapiens
Marx, P.F.; Havik, S.R.; Bouma, B.N.; Meijers, J.C.
Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor
J. Thromb. Haemost.
3
1293-1300
2005
Homo sapiens
Willemse, J.L.; Leurs, J.R.; Hendriks, D.F.
Fast kinetic assay for the determination of procarboxypeptidase U in human plasma
J. Thromb. Haemost.
3
2353-2355
2005
Homo sapiens
Matthews, K.W.; Mueller-Ortiz, S.L.; Wetsel, R.A.
Carboxypeptidase N: a pleiotropic regulator of inflammation
Mol. Immunol.
40
785-793
2004
Homo sapiens
Borgstroem, A.; Regner, S.
Active carboxypeptidase B is present in free form in serum from patients with acute pancreatitis
Pancreatology
5
530-536
2005
Homo sapiens
Bouma, B.N.; Mosnier, L.O.
Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis
Pathophysiol. Haemost. Thromb.
33
375-381
2005
Homo sapiens, Mus musculus
Bouma, B.N.; Meijers, J.C.
New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R)
Semin. Hematol.
41 Suppl 1
13-19
2004
Homo sapiens
Mousa, H.A.; Downey, C.; Alfirevic, Z.; Toh, C.H.
Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy
Thromb. Haemost.
92
1025-1031
2004
Homo sapiens
Frere, C.; Morange, P.E.; Saut, N.; Tregouet, D.A.; Grosley, M.; Beltran, J.; Juhan-Vague, I.; Alessi, M.C.
Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact
Thromb. Haemost.
94
373-379
2005
Homo sapiens
Leurs, J.; Hendriks, D.
Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease
Thromb. Haemost.
94
471-487
2005
Homo sapiens
Donmez, A.; Aksu, K.; Celik, H.A.; Keser, G.; Cagirgan, S.; Omay, S.B.; Inal, V.; Aydin, H.H.; Tombuloglu, M.; Doganavsargil, E.
Thrombin activatable fibrinolysis inhibitor in Behcets disease
Thromb. Res.
115
287-292
2005
Homo sapiens
Do, Y.H.; Gifford-Moore, D.S.; Beight, D.W.; Rathnachalam, R.; Klimkowski, V.J.; Warshawsky, A.M.; Lu, D.
Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives
Thromb. Res.
116
265-271
2005
Homo sapiens
Bjoerkman, J.A.; Abrahamsson, T.I.; Nerme, V.K.; Mattsson, C.J.
Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis
Thromb. Res.
116
519-524
2005
Canis lupus familiaris
Uszynski, W.; Uszynski, M.; Zekanowska, E.
Thrombin activatable fibrinolysis inhibitor (TAFI) in human amniotic fluid. A preliminary study
Thromb. Res.
119
241-245
2006
Homo sapiens
Higuchi, T.; Nakamura, T.; Kakutani, H.; Ishii, H.
Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor
Biol. Pharm. Bull.
32
179-185
2009
Homo sapiens
Nielsen, V.G.
Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor
Blood Coagul. Fibrinolysis
19
283-287
2008
Homo sapiens
Kilicarslan, A.; Yavuz, B.; Guven, G.S.; Atalar, E.; Sahiner, L.; Beyazit, Y.; Kekilli, M.; Ozer, N.; Oz, G.; Haznedaroglu, I.C.; Sozen, T.
Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome
Blood Coagul. Fibrinolysis
19
310-314
2008
Homo sapiens
Nielsen, V.G.; Kirklin, J.K.
Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII
Blood Coagul. Fibrinolysis
19
793-800
2008
Homo sapiens
Matus, V.; Willemse, J.; Quiroga, T.; Goycoolea, M.; Aranda, E.; Panes, O.; Pereira, J.; Hendriks, D.; Mezzano, D.
Procarboxypeptidase U (TAFI) and the Thr325Ile proCPU polymorphism in patients with hereditary mucocutaneous hemorrhages
Clin. Chim. Acta
401
158-161
2009
Homo sapiens
Koldas, M.; Gummus, M.; Seker, M.; Seval, H.; Hulya, K.; Dane, F.; Kural, A.; Gumus, A.; Salepci, T.; Turhal, N.S.
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer
Clin. Lung Cancer
9
112-115
2008
Homo sapiens (Q8IWV7), Homo sapiens
Brouns, R.; Heylen, E.; Sheorajpanday, R.; Willemse, J.L.; Kunnen, J.; De Surgeloose, D.; Hendriks, D.F.; De Deyn, P.P.
Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients
Clin. Neurol. Neurosurg.
111
165-170
2009
Homo sapiens
Muto, Y.; Suzuki, K.; Iida, H.; Sakakibara, S.; Kato, E.; Itoh, F.; Kakui, N.; Ishii, H.
EF6265, a novel thrombin-activatable fibrinolysis inhibitor-a inhibitor, protects against sepsis-induced organ dysfunction in rats
Crit. Care Med.
37
1744-1749
2009
Rattus norvegicus
Akinci, B.; Demir, T.; Saygili, S.; Yener, S.; Alacacioglu, I.; Saygili, F.; Bayraktar, F.; Yesil, S.
Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy
Diabetes Res. Clin. Pract.
81
93-96
2008
Homo sapiens
Erem, C.; Ucuncu, O.; Yilmaz, M.; Kocak, M.; Nuhoglu, I.; Ersoz, H.O.
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism
Endocrine
35
75-80
2009
Homo sapiens
Koutroubakis, I.E.; Sfiridaki, A.; Tsiolakidou, G.; Coucoutsi, C.; Theodoropoulou, A.; Kouroumalis, E.A.
Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease
Eur. J. Gastroenterol. Hepatol.
20
912-916
2008
Homo sapiens
Erdogan, M.; Karadeniz, M.; Alper, G.E.; Tamsel, S.; Uluer, H.; Caglayan, O.; Saygili, F.; Yilmaz, C.
Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome
Exp. Clin. Endocrinol. Diabetes
116
143-147
2008
Homo sapiens
Karakurt, F.; Gumus, I.I.; Bavbek, N.; Kargili, A.; Koca, C.; Selcoki, Y.; Ozbek, M.; Kosar, A.; Akcay, A.
Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome
Gynecol. Endocrinol.
24
491-497
2008
Homo sapiens
Ikeda, A.; Gabazza, E.C.; Morser, J.; Imoto, I.; Kuroda, M.; DAlessandro-Gabazza, C.N.; Hara, K.; Ruiz, D.B.; Bernabe, P.G.; Katsurahara, M.; Toda, M.; Kobayashi, Y.; Yano, Y.; Sumida, Y.; Suzuki, K.; Taguchi, O.; Takei, Y.
Presence of thrombin-activatable fibrinolysis inhibitor in Helicobacter pylori-associated gastroduodenal disease
Helicobacter
14
147-155
2009
Homo sapiens
Cetinkalp, S.; Tobu, M.; Karadeniz, M.; Buyukkececi, F.; Yilmaz, C.
The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis
Intern. Med.
48
281-285
2009
Homo sapiens
Willemse, J.L.; Brouns, R.; Heylen, E.; De Deyn, P.P.; Hendriks, D.F.
Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy
J. Thromb. Haemost.
6
200-202
2008
Homo sapiens
Marx, P.F.; Plug, T.; Havik, S.R.; Moergelin, M.; Meijers, J.C.
The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?
J. Thromb. Haemost.
7
445-452
2009
Homo sapiens
Foley, J.H.; Nesheim, M.E.
Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor
J. Thromb. Haemost.
7
453-459
2009
Homo sapiens
Miah, M.F.; Boffa, M.B.
Functional analysis of mutant variants of thrombin-activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin
J. Thromb. Haemost.
7
665-672
2009
Homo sapiens
Sanglas, L.; Valnickova, Z.; Arolas, J.L.; Pallares, I.; Guevara, T.; Sola, M.; Kristensen, T.; Enghild, J.J.; Aviles, F.X.; Gomis-Rueth, F.X.
Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis
Mol. Cell
31
598-606
2008
Homo sapiens, Bos taurus (Q2KIG3), Bos taurus
Soni, H.; Sharma, A.; Bhatt, S.; Jain, M.R.; Patel, P.R.
Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats
Pharmacology
82
304-309
2008
Rattus norvegicus (Q9EQV9)
Folkeringa, N.; Coppens, M.; Veeger, N.J.; Bom, V.J.; Middeldorp, S.; Hamulyak, K.; Prins, M.H.; Bueller, H.R.; van der Meer, J.
Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels
Thromb. Haemost.
100
38-44
2008
Homo sapiens
Bruno, N.E.; Yano, Y.; Takei, Y.; Qin, L.; Suzuki, T.; Morser, J.; D'Alessandro-Gabazza, C.N.; Mizoguchi, A.; Suzuki, K.; Taguchi, O.; Gabazza, E.C.; Sumida, Y.
Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency
Thromb. Haemost.
100
90-100
2008
Mus musculus (Q9JHH6)
Heylen, E.; Miljic, P.; Willemse, J.; Djordjevic, V.; Radojkovic, D.; Colovic, M.; Elezovic, I.; Hendriks, D.
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia
Thromb. Res.
124
427-432
2009
Homo sapiens
Heylen, E.; Van Goethem, S.; Willemse, J.; Olsson, T.; Augustyns, K.; Hendriks, D.
Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma
Anal. Biochem.
396
152-154
2010
Homo sapiens
Heylen, E.; Van Goethem, S.; Augustyns, K.; Hendriks, D.
Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay
Anal. Biochem.
403
114-116
2010
Homo sapiens
Fernandez, D.; Pallares, I.; Vendrell, J.; Aviles, F.X.
Progress in metallocarboxypeptidases and their small molecular weight inhibitors
Biochimie
93
1484-1500
2010
Homo sapiens
Willemse, J.L.; Heylen, E.; Nesheim, M.E.; Hendriks, D.F.
Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?
J. Thromb. Haemost.
7
1962-1971
2009
Homo sapiens
Brouns, R.; Heylen, E.; Willemse, J.L.; Sheorajpanday, R.; De Surgeloose, D.; Verkerk, R.; De Deyn, P.P.; Hendriks, D.F.
The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome
J. Thromb. Haemost.
8
75-80
2010
Homo sapiens
Leenaerts, D.; Bosmans, J.M.; van der Veken, P.; Sim, Y.; Lambeir, A.M.; Hendriks, D.
Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction
J. Thromb. Haemost.
13
2227-2232
2015
Homo sapiens (Q96IY4), Homo sapiens
Leenaerts, D.; Loyau, S.; Mertens, J.C.; Boisseau, W.; Michel, J.B.; Lambeir, A.M.; Jandrot-Perrus, M.; Hendriks, D.
Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different invitro models
J. Thromb. Haemost.
16
2057-2069
2018
Homo sapiens (Q96IY4)
Mertens, J.; Claesen, K.; Leenaerts, D.; Sim, Y.; Lambeir, A.; Hendriks, D.
Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis
J. Thromb. Haemost.
17
878-884
2019
Homo sapiens (Q96IY4)
html completed
